The company had encouraging results for its breast cancer tests and provided an update on the development of its bladder cancer test.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
Illumina plans to speed up the process of making Grail an independent company and will no longer have representation on its board of directors.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.
A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.
In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.
Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.
Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.
In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.